Two drugs developed by Disc Medicine (IRON) and Sanofi (SNY) are facing delays in their review timelines due to safety and efficacy concerns in the U.S. after being selected for the FDA Commissioner’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results